| Title: | Idarubicin-loaded drug-eluting microspheres transarterial chemoembolization for intermediate stage hepatocellular carcinoma : safety, efficacy, and pharmacokinetics |
|---|
| Authors: | ID Koršič, Špela (Author)
ID Osredkar, Joško (Author)
ID Šmid, Lojze (Author)
ID Steblovnik, Klemen (Author)
ID Popović, Mark (Author)
ID Locatelli, Igor (Author)
ID Trontelj, Jurij (Author)
ID Popović, Peter (Author) |
|---|
| Files: |  URL - Source URL, visit https://sciendo.com/article/10.2478/raon-2024-0052
 PDF - Presentation file, download (711,05 KB)
MD5: E42B65FFBEE84FCE33417A905F59C59A
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  DRO - Association of Radiology and Oncology
|
|---|
| Abstract: | Background: Transarterial chemoembolization (TACE) is the treatment of choice for the intermediate stage hepatocellular carcinoma (HCC). Doxorubicin remains the most used chemotherapeutic agent in TACE, although in vitro screening has demonstrated that idarubicin exhibits greater cytotoxicity against HCC. This study aimed to evaluate safety, efficacy, and pharmacokinetics of idarubicin-loaded drug-eluting microspheres TACE (DEMIDA-TACE) in intermediate stage HCC patients. Patients and methods: Between September 2019 and December 2021, 31 consecutive intermediate stage HCC patients (96.8% cirrhotic) were included to this study. 2 mL of LifePearl™ microspheres (100 μm) loaded with 10 mg of 1 mg/mL idarubicin were used for treatment. The adverse events, objective response rate (ORR), progression free survival (PFS), time to TACE untreatable progression (TTUP), median overall survival (mOS), and pharmacokinetics were evaluated. Results: There were 68 TACE procedures performed. Adverse events grade ≥ 3 were noted after 29.4% procedures. The ORR was 83.9%, median PFS and TTUP were 10.5 months (95% CI: 6.8-14.3 months) and 24.6 months (95% CI: 11.6-37.6 months), respectively. Median OS was 36.0 months (95% CI: 21.1-50.9 months). Significant differences between patients achieving objective response (OR) and those with progressive disease were observed regarding idarubicinol and combined idarubicin-idarubicinol plasma concentrations at 72 hours post-procedure, higher plasma concentrations were observed in patients achieving OR (p = 0.014 and 0.014; cut-off values 1.2 and 1.29 ng/mL, respectively). Conclusions: DEMIDA-TACE emerges as a safe and effective method of treatment for the intermediate stage HCC with low rates of adverse events alongside high tumor response, favourable disease control and overall survival. Idarubicinol and combined idarubicin-idarubicinol plasma concentrations at 72 hours post-procedure may serve as prognostic factors for achieving OR. |
|---|
| Keywords: | drug-eluting microspheres transarterial chemoembolization, efficacy, hepatocellular carcinoma, idarubicin, pharmacokinetics, safety |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Publication date: | 01.12.2024 |
|---|
| Publisher: | Association of Radiology and Oncology |
|---|
| Year of publishing: | 2024 |
|---|
| Number of pages: | str. 517-526, VII |
|---|
| Numbering: | Vol. 58, no. 4 |
|---|
| Source: | Ljubljana |
|---|
| PID: | 20.500.12556/DiRROS-30474  |
|---|
| UDC: | 616-006 |
|---|
| ISSN on article: | 1318-2099 |
|---|
| DOI: | 10.2478/raon-2024-0052 |
|---|
| COBISS.SI-ID: | 210906883 |
|---|
| Note: | Soavtorji: Josko Osredkar, Alojz Smid, Klemen Steblovnik, Mark Popovic, Igor Locatelli, Jurij Trontelj, Peter Popovic;
|
|---|
| Publication date in DiRROS: | 26.06.2026 |
|---|
| Views: | 141 |
|---|
| Downloads: | 101 |
|---|
| Metadata: |    |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
